Stock Events

Stock Events

Can-Fite Biopharma 

$2.23
20
-$0.12-5.11% Friday 20:00
+$0.01+0.32%Friday 23:56After hours

Statistics

Day High
2.25
Day Low
2.24
52W High
13.4
52W Low
2.23
Volume
2,079
Avg. Volume
-
Mkt Cap
4.78M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27AugExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q4 2025
Q2 2026
-2.99
-1.99
-0.99
0
Expected EPS
-0.165
Actual EPS
-0.165

Financials

-2,426.67%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
405,000Revenue
-9.83MNet Income

Analyst Ratings

7.50Average Price Target
The highest estimate is 8.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CANF. It's not an investment recommendation.
Apple
2
AAPL
Microsoft
2
MSFT
Realty Income
2
O
Tesla
2
TSLA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences is a biopharmaceutical company that competes in the development of drugs in areas such as inflammation and oncology, similar to Can-Fite's focus areas.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie operates in the same therapeutic areas as Can-Fite, including inflammation and cancer, making it a direct competitor in drug development.
AMGEN
AMGN
Mkt Cap236.38B
Amgen focuses on innovative therapeutics in areas like oncology and inflammation, directly competing with Can-Fite's product pipeline.
Bristol-Myers Squibb
BMY
Mkt Cap136.49B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines in cancer and immune-inflammatory diseases, overlapping with Can-Fite's interests.
Pfizer
PFE
Mkt Cap162.16B
Pfizer engages in the discovery, development, and manufacture of healthcare products including medicines and vaccines for immunology and oncology, competing with Can-Fite.
Merck
MRK
Mkt Cap370.89B
Merck operates in the pharmaceutical industry focusing on cancer and inflammatory diseases, making it a competitor to Can-Fite in these therapeutic areas.
Novartis
NVS
Mkt Cap304.1B
Novartis focuses on a broad range of healthcare areas including advanced therapy platforms in oncology and rheumatology, competing with Can-Fite's research and development.
Roche
RHHBY
Mkt Cap334.28B
Roche develops and markets medications and diagnostic instruments in oncology, immunology, and infectious diseases, areas that Can-Fite is also targeting.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global, science-led biopharmaceutical business that operates in the main therapy areas of cancer and autoimmune diseases, directly competing with Can-Fite.
Johnson & Johnson
JNJ
Mkt Cap663.28B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for a wide range of diseases, including those in Can-Fite's focus areas, making it a competitor.

About

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Show more...
CEO
Motti Farbstein
Employees
5
Country
Israel
ISIN
US13471N4097
WKN
000A3D4G4

Listings

STU
DE
CF5.STU
XASE
US
CANF
TA
IL
CANF.TA
BOATS
BOATS
CANF.BOATS

0 Comments

Share your thoughts

FAQ

What is Can-Fite Biopharma stock price today?▼
The current price of CANF is $2.23 USD — it has decreased by -5.11% in the past 24 hours. Watch Can-Fite Biopharma stock price performance more closely on the chart.
What is Can-Fite Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XASE exchange Can-Fite Biopharma stocks are traded under the ticker CANF.
Is Can-Fite Biopharma stock price growing?▼
CANF stock has fallen by -30.75% compared to the previous week, the month change is a -35.17% fall, over the last year Can-Fite Biopharma has showed a -82.88% decrease.
What is Can-Fite Biopharma market cap?▼
Today Can-Fite Biopharma has the market capitalization of 4.78M
When is the next Can-Fite Biopharma earnings date?▼
Can-Fite Biopharma is going to release the next earnings report on April 01, 2027.
What were Can-Fite Biopharma earnings last quarter?▼
CANF earnings for the last quarter are -0.17 USD per share, whereas the estimation was -0.17 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Can-Fite Biopharma revenue for the last year?▼
Can-Fite Biopharma revenue for the last year amounts to 405,000 USD.
What is Can-Fite Biopharma net income for the last year?▼
CANF net income for the last year is -9.83M USD.
How many employees does Can-Fite Biopharma have?▼
As of September 07, 2026, the company has 5 employees.
In which sector is Can-Fite Biopharma located?▼
Can-Fite Biopharma operates in the Health & Wellness sector.
When did Can-Fite Biopharma complete a stock split?▼
The last stock split for Can-Fite Biopharma was on January 05, 2026 with a ratio of 1:20.
Where is Can-Fite Biopharma headquartered?▼
Can-Fite Biopharma is headquartered in Ramat Gan, Israel.